Le Lézard
Classified in: Health, Science and technology, Business
Subject: TNM

MYONEX CLOSES CREAPHARM ACQUISITION EXPANDING GLOBAL SERVICES


HORSHAM, Pa., May 2, 2024 /PRNewswire/ -- Myonex has completed the previously announced acquisition of CREAPHARM's pharmaceutical services business. This transaction combines capabilities and flexibility to serve pharmaceutical and biotech companies in both clinical and commercial stages, including companies managing Advanced Therapies. Creapharm's clinical packaging and distribution services, commercial packaging operations and bioservices will now be known as Creapharm, a Myonex company.

Myonex has completed the previously announced acquisition of CREAPHARM's pharmaceutical services business

"We are thrilled to have completed the acquisition of Creapharm, a milestone that expands our services and enhances our capabilities for clients and the industry. Together, we are poised to meet the dynamic needs of our clients with agility, flexibility, and reliability," stated James Lovett, CEO of Myonex.

"We are excited to welcome Eric Placet, the visionary founder and former CEO of CREAPHARM, to the Myonex Board of Directors. His decision to reinvest in the company is a testament to our shared commitment to excellence and innovation. Additionally, we are pleased to announce the appointment of Carla Da Costa as our Chief Operating Officer, further strengthening our executive team as we continue to drive growth and deliver exceptional value to our clients," stated Mike Cohen, Executive Chairman, Myonex. Edouard Placet will continue in his role as Strategic Development Director of Myonex.

Myonex was advised by McDermott, Will & Emery in France along with Troutman Pepper in the United States as its legal advisors, and Crosstree Capital Partners as its financial advisors, in its acquisition of Creapharm. Creapharm was advised in France on the M&A legal part by ARST Avocats and on the fiscal and corporate legal part by Nomodos. Additionally, Nelson Mullins acted as US legal advisor and Rothschild&Co as financial advisor.

About Myonex

Myonex is a leading global complete clinical trial supply company offering tailored solutions in central and local drug sourcing, packaging, labeling, and ancillary and equipment supply to support each trial's specific requirements and complexities. With locations in the US, Germany, & UK, we partner with pharmaceutical and biotechnology companies, contract research organizations (CROs), and other clinical trial service providers seeking a flexible, comprehensive solution for their trial supply needs. Learn more at www.myonex.com

About Creapharm
With decades of experience in global clinical trial supply management, Creapharm supports Pharma and Biotech key players with customized solutions. Creapharm has a strong expertise in cold-chain management and recently developed ultra-cold solutions to handle biologicals and ATMP supply chain management. For marketed health products, Creapharm offers expert commercial packaging services to pharmaceutical and food supplement industries. Learn more at www.creapharm-pharma.com.

CONTACT: 
Maryanne Walsh
(+1) 267-307-0876

SOURCE Myonex


These press releases may also interest you

at 08:17
The Children's Tumor Foundation (CTF) announces nearly 400 world-famous buildings, bridges, waterfalls, castles and architectural icons are participating in this year's Shine a Light on NF campaign and will show their support in the global fight...

at 08:10
Guardant Health, Inc. , a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 215,601 shares of...

at 08:08
Victoria Eye Center/Victoria Surgery Center/Victoria Vision Center ("VEC") is writing to provide information regarding an event that involves certain information relating to personal health information.  On March 21, 2024, VEC became aware that...

at 08:05
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 17,...

at 08:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role...

at 08:05
Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today announced that it will host a call for analysts and investors after market close on May 22, 2024. The company has scheduled a...



News published on and distributed by: